Why Medication-Assisted Treatment Is Evolving
For many people recovering from opioid addiction, daily medication routines can be challenging. Missed doses, misuse, or diversion may increase relapse risk — especially early in recovery. Injectable buprenorphine was developed to solve these problems by providing steady, long-acting medication support without daily dosing.
At Sanctuary Treatment Center, injectable buprenorphine is one of several medication-assisted treatment (MAT) options used to support safe, sustainable recovery from opioid use disorder.
What Is Injectable Buprenorphine?
Injectable buprenorphine is a long-acting formulation of buprenorphine administered by a medical provider, typically once per month. Common FDA-approved options include:
- Sublocade® (monthly injection)
- Brixadi® (weekly or monthly injection)
Once injected, buprenorphine is slowly released into the bloodstream, maintaining stable opioid receptor coverage without daily pills or films (FDA, 2023).
How Injectable Buprenorphine Works
Buprenorphine is a partial opioid agonist, meaning it:
- Reduces cravings
- Prevents withdrawal symptoms
- Blocks the effects of full opioids
- Lowers overdose risk
Injectable versions create a consistent medication level, avoiding the peaks and crashes sometimes associated with oral or sublingual dosing (NIDA, 2023).
Injectable Buprenorphine vs. Sublingual Buprenorphine
| Feature | Injectable Buprenorphine | Sublingual Buprenorphine |
|---|---|---|
| Dosing | Weekly or monthly | Daily |
| Diversion Risk | None | Possible |
| Adherence | Provider-administered | Patient-managed |
| Craving Stability | Very stable | Can fluctuate |
| Best For | Early recovery, relapse prevention | Flexible long-term use |
Both options are effective, but injectable buprenorphine can be especially helpful for individuals who struggle with daily medication adherence.
Who Is Injectable Buprenorphine Best For?
Injectable buprenorphine may be a strong option for people who:
- Have a history of relapse
- Struggle with daily medication routines
- Want discreet treatment without daily reminders
- Are transitioning out of residential care
- Have concerns about misuse or diversion
Sanctuary’s medical team carefully evaluates each client to determine whether injectable MAT aligns with their recovery goals.
Benefits of Injectable Buprenorphine
- Improved adherence: No daily dosing decisions
- Lower relapse risk: Steady receptor coverage
- Reduced stigma: No daily medication handling
- Safer storage: Nothing to lose, misuse, or share
- Better focus on therapy: Less mental energy spent managing medication
Studies show long-acting buprenorphine improves treatment retention and reduces illicit opioid use compared to short-acting options (Ling et al., 2020).
Limitations and Considerations
Injectable buprenorphine may not be appropriate for everyone. Considerations include:
- Must first stabilize on sublingual buprenorphine
- Injections must be administered by a provider
- Less flexible dosing adjustments
- Possible injection-site reactions
Medication decisions should always be individualized and medically supervised.
How Sanctuary Treatment Center Uses Injectable MAT
At Sanctuary, injectable buprenorphine is integrated into a whole-person recovery plan, not used as a stand-alone solution. Treatment includes:
- Medical stabilization and monitoring
- Individual and group therapy
- Trauma-informed care
- Relapse prevention planning
- Aftercare coordination
Our goal is not lifelong dependence, it’s stability, healing, and autonomy at the pace that best supports long-term recovery.
Common Myths About Injectable Buprenorphine
“It’s just replacing one drug with another.”
Buprenorphine stabilizes brain chemistry without producing euphoria when used as prescribed, allowing people to rebuild their lives (NIDA, 2023).
“Once you start injections, you can’t stop.”
False. Many people taper off injectable MAT gradually under medical supervision.
“MAT means you’re not really sober.”
MAT is evidence-based treatment, endorsed by the CDC, SAMHSA, and NIH as a life-saving intervention.
Frequently Asked Questions
How long does injectable buprenorphine last?
Monthly formulations provide consistent coverage for about 28–30 days (FDA, 2023).
Can you feel the medication working?
Most people report feeling stable and “normal,” not high or sedated.
Is injectable buprenorphine safer than oral forms?
It reduces misuse and diversion risk and lowers overdose risk when taken as prescribed.
Sources
U.S. Food and Drug Administration. (2024). Information about medications for opioid use disorder (MOUD). https://www.fda.gov/drugs/information-drug-class/information-about-medications-opioid-use-disorder-moud
U.S. Food and Drug Administration. (2023, May 23). FDA approves new buprenorphine treatment option for opioid use disorder. https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder
Substance Abuse and Mental Health Services Administration. (2026). What is buprenorphine? Side effects, treatment & use. https://www.samhsa.gov/substance-use/treatment/options/buprenorphine
Substance Abuse and Mental Health Services Administration. (2021). TIP 63: Medications for opioid use disorder. https://library.samhsa.gov/product/tip-63-medications-opioid-use-disorder/pep21-02-01-002
National Institute on Drug Abuse. (2025). Medications for opioid use disorder. National Institutes of Health. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
Nunes, E. V., Comer, S. D., Lofwall, M. R., Walsh, S. L., Peterson, S., Tiberg, F., Hjelmström, P., & Budilovsky-Kelley, N. R. (2024). Extended-release injection vs sublingual buprenorphine for opioid use disorder with fentanyl use: A post hoc analysis of a randomized clinical trial. JAMA Network Open. https://pubmed.ncbi.nlm.nih.gov/38916892/
D’Onofrio, G., Hawk, K. F., Perrone, J., Herring, A. A., O’Connor, P. G., Chawarski, M. C., Owens, P. H., Martel, S., Melnick, E. R., O’Connor, L. M., Pantalon, M. V., Hawk, K., Cowan, E., & Fiellin, D. A. (2024). Extended-release 7-day injectable buprenorphine for patients with minimal to mild opioid withdrawal. JAMA Network Open. https://pubmed.ncbi.nlm.nih.gov/38976265/
Shiwach, R., Campbell, A. N. C., Nunes, E. V., Comer, S. D., Lofwall, M. R., Walsh, S. L., Peterson, S., Tiberg, F., Hjelmström, P., & Rotrosen, J. (2025). Rapid vs standard induction to injectable extended-release buprenorphine: A randomized clinical trial. JAMA Network Open. https://pmc.ncbi.nlm.nih.gov/articles/PMC12522003/
Martin, E., Nielsen, S., Larance, B., Lintzeris, N., Bruno, R., Degenhardt, L., & Hides, L. (2022). Long-acting injectable buprenorphine for opioid use disorder. Drug and Alcohol Review. https://pubmed.ncbi.nlm.nih.gov/35365366/
Lee, J. D., Malone, M., McDonald, R., Cheng, A., Vasudevan, K., Tofighi, B., Garment, A., Porter, B., Goldfeld, K. S., & Rotrosen, J. (2021). Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail. JAMA Network Open. https://pubmed.ncbi.nlm.nih.gov/34495340/
Ling, W., Nadipelli, V. R., Solem, C. T., Ronquest, N. A., Yeh, Y. C., Learned, S. M., Mehra, V., & Heidbreder, C. (2019). Patient-centered outcomes in participants of a buprenorphine monthly depot treatment trial. Patient Preference and Adherence. https://pubmed.ncbi.nlm.nih.gov/30844878/
U.S. Food and Drug Administration. (2024). BRIXADI risk assessment and risk mitigation review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/210136Orig1s000RiskR.pdf